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Abstract
Objective: Maternal recreational drug use may be associated with the development of fetal malformations such as
gastroschisis, brain and limb defects, the aetiology due to vascular disruption during organogenesis. Using forensic hair
analysis we reported evidence of recreational drug use in 18% of women with a fetal gastroschisis. Here we investigate this
association in a variety of fetal malformations using the same method.
Methods: In a multi-centre study, women with normal pregnancies (controls) and those with fetal abnormalities (cases)
gave informed consent for hair analysis for recreational drug metabolites using mass spectrometry. Hair samples cut at the
root were tested in sections corresponding to 3 month time periods (pre and periconceptual period).
Results: Women whose fetus had gastroschisis, compared to women with a normal control fetus, were younger (mean age
23.786SD4.79 years, 18–37 vs 29.796SD6 years, 18–42, p = 0.00001), were more likely to have evidence of recreational drug
use (15, 25.4% vs 21, 13%, OR2.27, 95thCI 1.08–4.78, p = 0.028), and were less likely to report periconceptual folic acid use
(31, 53.4% vs 124, 77.5%, OR0.33, 95thCI 0.18–0.63, p = 0.001). Age-matched normal control women were no less likely to test
positive for recreational drugs than women whose fetus had gastroschisis. After accounting for all significant factors, only
young maternal age remained significantly associated with gastroschisis. Women with a fetus affected by a non-neural tube
central nervous system (CNS) anomaly were more likely to test positive for recreational drugs when compared to women
whose fetus was normal (7, 35% vs 21, 13%, OR3.59, 95th CI1.20–10.02, p = 0.01).
Conclusions: We demonstrate a significant association between non neural tube CNS anomalies and recreational drug use
in the periconceptual period, first or second trimesters, but we cannot confirm this association with gastroschisis. We
confirm the association of gastroschisis with young maternal age.
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Introduction
Recreational drug use is reported to be associated with some
fetal malformations, in particular, gastroschisis, brain and isolated
limb defects. The Chief Medical Officer’s annual report in 2004
highlighted a nearly three-fold rise in the prevalence of gastros-
chisis cases reported in the UK in the last 10 years [1]. Many
studies have demonstrated a marked association between the
incidence of gastroschisis and young maternal age [2], as well as
the use of recreational drugs periconceptually and in pregnancy
[3,4]. These data come from epidemiological studies and
questionnaire-based assessment of mothers and urine analysis, all
of which are subject to poor ascertainment and unreliability [5–7].
In a small study using objective maternal hair root analysis for
drug metabolites, we previously found evidence of periconceptual
and/or first trimester maternal recreational drug use in 18% of
cases with a diagnosis of gastroschisis compared with 0% in
normal controls [8]. During this study we also detected evidence of
recreational drug use in a few women with other fetal abnormal-
ities, but the numbers were too small to permit any statistical
analysis. It is important to expand and extend the study to
examine the association with other congenital malformations that
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may be caused by vascular disruption, in order to objectively
determine the role of recreational drugs in their aetiology.
There is evidence from animal studies that drugs such as
metamphetamine and cocaine can cause a variety of fetal
malformations including limb defects, brain anomalies, and
abnormalities of the lip [9–12]. Observational studies have also
indicated a possible association with fetal malformations in the
human fetus including facial clefts, renal abnormalities, gastros-
chisis, and cardiac anomalies [13–16], and there are case reports
of associated renal [17] and facial abnormalities [18]. An increased
risk of gastroschisis and small bowel atresia has been associated
with maternal use of vasoconstrictive drugs such as pseudoephed-
rine, phenylpropanol-amine, ephedrine, and methylenedioxy-
methamphetamine (MDMA) [19] as well as cocaine [20]. Vascular
disruption has been proposed as a possible aetiology in the
development of these abnormalities. The studies are small,
however, and based on self-reporting of drug-taking with poor
documentation of the timing of drug use, such that it is not possible
to draw definitive conclusions.
The aim of this study was to determine whether maternal
recreational drug use is a factor for the development of congenital
fetal malformations that may be caused by vascular disruption
such as gastroschisis, cleft lip and palate, renal, central nervous
system and isolated limb defects. We hypothesized that women
whose fetus has such a congenital malformation would be
significantly more likely to have evidence of periconceptual, first
or second trimester recreational drug use when compared to
women whose fetus has an anomaly with no potential vascular
aetiology or a normal fetus. Our previous study used mass
spectrometry for the analysis of drug metabolites in maternal hair,
the gold standard technique for forensic hair analysis that is highly
sensitive and specific. This technique allows the temporal
relationship between timing of drug exposure and embryogenesis
to be explored, since evidence of drug use is ‘stored’ in the
maternal hair for many months after ingestion, and the timing of
drug exposure can be calculated from the length of the hair in
which the drug is detectable [21,22]. Thus drug use that predates
embryogenesis and the development of fetal anomalies can be
identified. Using similar methodology we studied pregnant women
whose fetuses had a variety of congenital malformations, including
those thought to be associated with vascular disruption. In
particular we investigated the association with gastroschisis in a
larger cohort of affected pregnancies.
Methods
Recruitment
This was a multicentre study (2006–2010). Women whose fetus
had a congenital anomaly diagnosed on ultrasound scan were
recruited as cases; those whose fetus was normal were recruited as
controls. Cases were separated into two groups based on whether
the anomaly had previously been associated with vascular
disruption in preclinical and clinical studies [9–18] (see below).
Ethics Statement
Informed written consent (Study number 05/Q0502/129,
‘‘Recreational drugs as aetiological factors in fetal malformations’’
approved by the Joint UCL/UCLH Committees on the Ethics of
Human Research) was obtained from women attending the Fetal
Medicine Units (FMUs) at University College London Hospital
(UCLH), King’s College Hospital (KCH), St Michael’s Hospital
Bristol (Bristol), Birmingham Women’s Hospital (Birmingham),
and the Cleft Lip and Palate Clinic at Great Ormond Street
Hospital for Children, London (GOSH). Women whose fetus had
a diagnosis of an abnormality were recruited sequentially from
each Fetal Medicine Unit:
We recruited three groups of women:
(1) Vascular Disruption Cases: those whose fetus had defects
thought to be associated with vascular disruption (gastroschi-
sis, isolated transverse limb defects, bowel atresia, facial cleft,
cardiac and renal anomalies, and central nervous system
anomaly (CNS) other than neural tube defect (NTD) ‘‘non-
NTD CNS anomaly’’).
(2) Non-Vascular Disruption Control Group: those whose fetus
had a defect not thought to have a vascular disruption
aetiology and where there is no evidence of an association
with recreational drug use (exomphalos, NTD, talipes and
congenital diaphragmatic hernia (CDH), and aneuploidy,
single gene disorders or genetic syndromes).
(3) Normal Control Group: women whose fetus were normally-
formed and had a normal karyotype.
Women in the normal control group were recruited at random
in the antenatal clinics in the same hospitals and over the same
time period after a normal detailed second trimester ultrasound
scan had been performed. To take account of the younger age of
women with pregnancies complicated by fetal gastroschisis, we
ensured that each case of gastroschisis had a woman from the
Normal Control Group of the same maternal age range (62 years)
recruited. In all cases and controls, ultrasound findings were
confirmed after delivery by paediatric examination at birth,
karyotyping and/or autopsy. There were no cases of women being
recruited into the study on the basis of ultrasound findings that
were not confirmed after delivery. Gestational age was confirmed
by first trimester ultrasound in all women.
Information on women who declined to participate after being
approached by the research team was collected prospectively.
Women with hair shorter than 3 cm or those known to have hair
extensions were not recruited. The Research Ethics Committee
did not give permission to question the women about possible
recreational drug use and self-reported drug use was not
documented.
Questionnaire
The primary aim of the study was to objectively investigate
recreational drug use. However other social factors have
previously been associated with fetal abnormalities and we
therefore collected data from all women via a short questionnaire
about these factors to enable adjustment as confounders in the
statistical analysis: social history, smoking habits, alcohol use, use
of over-the-counter and prescription drugs, including folic acid,
paracetamol (acetaminophen) and non-steroidal anti-inflammato-
ry drugs (NSAIDs) just prior to and during the current pregnancy.
We used the Index of Multiple Deprivation (IMD) score, which
combines a number of indicators chosen to cover a range of
economic, social and housing issues, into a single deprivation score
for individual neighbourhoods. The ID 2007 average IMD score
was used (population weighted average of the combined IMD
scores for the Super Output Areas in a district) and was derived
from the woman’s postcode according to National Statistics data.
Information on their past obstetric history was collected from their
antenatal booking history.
Hair analysis method
Hair sampling and analysis was performed as previously
described [8], after completion of the pregnancy, by Tricho-Tech
Limited, Cardiff, UK. Once consent was obtained, a sample of
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hair was cut from the vertex (the crown) of the head as close to the
scalp as possible. A sample of at least 50 hairs was obtained. The
cut root ends were aligned and the sample was placed on
aluminium foil with the cut root ends projecting about 1.5 cm
from a marked end for clear identification. The foil was folded
around the hair and securely kept in place. The sample was
carefully packaged, barcoded for identification, sealed and sent to
Tricho-Tech Limited for analysis of drug compounds which was
performed blind to the clinical data pertaining to each case. The
hair sample analysis was performed after washing the sample to
remove any potential external contamination. The samples were
then dried and cut into three 3-cm sections. Each section was
weighed and the samples were analysed by enzyme-linked
immunosorbent assay (ELISA) for the individual drug groups
and any presumptive positives confirmed by gas chromatography
with mass spectrometry (GCMS). GCMS is a powerful and widely
used method of identifying and measuring analytes. Compounds
become separated travelling through a GC column and those
separated compounds enter the mass spectrometer, which creates
charged particles (ions) from molecules. It then analyses those ions
to provide information about chemical structure and molecular
weight. Mass spectral patterns are reproducible and the mass
spectra of known compounds are used to identify unknown
substances.
Assays were performed for the following drugs or drug groups:
amphetamine and its derivatives, such as methylenedioxy-meth-
amphetamine (MDMA or ‘ecstasy’), barbiturates, benzodiaze-
pines, cannabis and its metabolites, cocaine, ketamine, and
opiates, including morphine, codeine, and dihydrocodeine. The
limit of detection of the screening immunoassays was set at 10 ng/
ml of hair extract. On a typical weight of sample of 10 mg this
produces a limit of detection of 1 ng/mg of hair for the screening
assays. The limit of detection of the GCMS confirmation assays
was 0.2 ng/mg of hair. The GCMS confirmation assay for cocaine
included measurement of cocaine and the major metabolite
benzoylecgonine.
Interpretation of hair results
The average rate of growth of hair is approximately 1 cm per
month (range 0.75–1.5 cm); therefore, a 3-cm section of hair
approximates to a three-month period [23–24]. Using this
information and the gestational age at hair sampling, the timing
of positive results was determined for each case and control and
categorised into three groups periconceptual, 1st trimester and 2nd
trimester (Figure 1). This method of analysis allows for the
detection of drug use that occurred around the time that fetal
organogenesis is being completed, when the development of a fetal
structural anomaly may occur. The method of analysis, however,
is not capable of reflecting exact drug doses taken, or the exact
time point within the three-month period that drugs were used.
For all analysed cases and controls, there was a hair sample
available for the equivalent periconceptual and trimester time
period, even for those women recruited in the late third trimester.
Sample size calculation
Statistical advice was sought prior to study commencement. We
based our sample size calculation on our primary hypothesis, that
women whose fetuses had gastroschisis would be significantly more
likely to have recreational drugs detected in their hair. In our
previous study we detected drug use in 18% of the gastroschisis
group [8]. Although no drug use was identified in the control
group, we assumed that some women in the control group would
be drug users. Between 2 and 3% of the world’s population and
5.5% of mothers in the US are known to take recreational drugs
[31]. Local figures (UCLH) suggested that 1–2% of booking
women were users of recreational drugs. We therefore assumed
that approximately 2% of the control group would be drug users.
Our sample size calculation was based on the Exact Sign Test: a
sample size of 68 pairs on a 1:1 basis or 46 gastroschisis Vascular
Disruption Cases and 95 Normal Controls on a 1:2 basis will have
90% power to detect a difference in proportions of 0.160 when the
proportion of discordant pairs is expected to be 0.180. Women
with pregnancies complicated by fetal gastroschisis are younger
than the average pregnant population. This means that the control
group for the gastroschisis cases would be on average younger than
that required for the other abnormality groups. We therefore
aimed to recruit 136 Normal Controls and 128 with ‘other’
abnormalities (Non-Vascular Disruption Control Group) to take
account of this and to give sufficient flexibility to do an age-
matched Normal Control group comparison for gastroschisis
cases. For other specific fetal defects within the Vascular
Disruption Group such as cleft lip and palate, congenital heart
defects, brain and renal anomalies there is no objective data
available on the level of drug use so we aimed to collect as many
samples as possible during the time frame of the study.
Statistics
To explore the relationship between the anomaly or group of
anomalies and a possible associated factor, women with the
Vascular Disruption type of fetal abnormality (renal, cardiac,
CNS, etc) were compared with women in the recruited population
whose fetus was normal (Normal Control group) and with those
whose fetus had a Non-Vascular Disruption type of anomaly. Chi-
squared tests (Pearson’s test or Fisher’s exact test for small
numbers), Mann Whitney U or t tests were used to study the
association between categorical or continuous variables. Binary
logistic regression was then used to study factors that were
independently found to be statistically significant, to explore
confounding variables. The statistics package SPSS PASW
Statistics version 21 was used for data analysis.
Results
Recruited women, exclusions and missing data
Eight women attending FMUs with a range of fetal abnormal-
ities declined to participate in the study after being approached by
the research team; no women with a normal fetus declined
participation. Of 677 women who were recruited and from whom
a hair sample was collected, three women were withdrawn due to
young maternal age (,18 years), two women subsequently
declined participation after hair collection, and 70 women were
excluded due to collection of insufficient hairs (n = 58) or hair
length too short (n = 12) for analysis. A further 85 women were
excluded because fetal outcome could not be confirmed (n= 20),
or the fetal anomaly did not fit the specified criteria (n = 65). For
the remaining 517 women, hair was sent for analysis. Data was
missing on ethnicity (25 cases, 4.8%), smoking and alcohol use (6
cases, 1.2%), over the counter medication use (4 cases, 0.8%) and
prescription medication (3 cases, 0.6%, Table 1).
Demographic data
The mean maternal age was 29.36 years (SD 6.23 years).
Further details of maternal social demographics including ethnicity
are given in Table 1. Self-reported over-the-counter (105 women,
20.3%) or prescribed drug use (172 women, 33.3%) was common,
with 13.7% of women currently smoking or drinking some alcohol
(15.1%, Table 1). Mean gestational age at hair sampling was
24.1866.45 weeks.
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Types of abnormalities
Table 2 shows the number and types of cases recruited by
group. Women whose fetus had a minor anomaly such as mild
ventriculomegaly, mild pyelectasis or echogenic foci were not
recruited. In the Vascular Disruption Cases, the largest proportion
recruited was women whose fetus had a gastroschisis (59 cases,
27.75% of Group). There were a variety of major cardiac, renal
and Non-NTD CNS cases, and ten Other Vascular Cases that
Figure 1. Hair samples comprising approximately 50 hairs were cut at the level of the hair root. From there they were divided into three
3 cm segments, representing the three time periods of interest: periconceptual (prior to the month in which conception took place and during the
month in which conception took place), 1st trimester (up to and including 12 weeks of gestation) and 2nd trimester (13 weeks of gestation onwards).
In this example the hair sample was cut when the woman was at the end of the 2nd trimester, giving a 3 cm length of hair for each time period of
study.
doi:10.1371/journal.pone.0111038.g001
Table 1. Population demographics.
Category
Vascular Cases
(n =213)
Normal Controls
(n=161)
Non Vascular
Controls (n=143) p
Total (%)
n=517
Maternal age in years, mean (median) 27.95 (28) 29.8 (30) 30.98 (30) ,0.00001 29.36 (29)
Maternal age range (years) 18–46 18–42 18–50 - 18–50
Ethnicity (no, %) Caucasian 151 (70.6) 125 (77.6) 103 (72.5) 0.131 (X2 12.5, 8df) 379 (73.3)
Asian 29 (13.6) 23 (14.3) 17 (12.0) 69 (13.3)
Black 12 (5.6) 8 (5.0) 12 (9.2) 33 (6.4)
Mixed 4 (1.9) 3 (1.9) 4 (2.8) 11 (2.1)
Missing data 18 (8.4) 2 (1.2) 5 (3.5) 25 (4.8)
Primiparous (no, %) 119 (55.9) 89 (55.3) 76 (53.1) 0.875 (X2 0.27, 2df) 284 (54?9)
Married or cohabiting (no, %) 168 (78.9) 135 (83.9) 112 (78.3) 0.385 (X2 1.91, 2df) 415 (80.3)
Currently employed (no, %) 136 (63.8) 119 (73.9) 102 (71.3) 0.09 (X2 4.83, 2df) 357 (69.1)
IMD score, mean (median) 26.61 (23.74) 26.89 (24.5) 25.10 (21.93) 0.523 26.27 (15.02)
IMD score range 2–83 2–59 1–68 - 1–83
Smoking: Current 32 (15.3) 21 (13.1) 18 (12.7) 0.74 (X2 0.61, 2df) 71 (13.9)
In the last 6 months 28 (13.4) 15 (9.4) 11 (7.7) 0.16 (X2 3.63, 2df) 54 (10.6)
Missing data 4 (1.9) 1 (0.6) 1 (0.6) - 6 (1.2)
Alcohol Use: Current 34 (15.9) 32 (19.9) 12 (8.4) 0.018 (X2 8.03, 2df) 78 (15.1)
In the last 6 months 81 (37.9) 77 (47.8) 46 (32.2) 0.019 (X2 7.96, 2df) 204 (39.5)
Missing data 4 (1.9) 1 (0.6) 1 (0.6) - 6 (1.2)
Over the counter: Folic acid 144 (67.3) 124 (77) 104 (72.7) 0.182 (X2 3.40, 2df) 372 (72.0)
Paracetamol (acetaminophen) 36 (16.9) 38 (23.6) 26 (18.2) 0.258 (X2 2.71, 2df) 100 (19.3)
NSAID use 11 (5.1) 11 (6.8) 7 (4.9) 0.721 (X2 0.65, 2df) 29 (5.6)
Codeine/dihydrocodeine* 9 (4.2) 2 (1.2) 5 (3.5) 0.239 (X2 2.86, 2df) 16 (3.1)
Missing data 2 (1.2) 1 (0.6) 1 (0.6) - 4 (0.8)
Prescription medication: Antibiotics 29 (13.6) 22 (13.7) 26 (18.2) 0.735 (X2 0.62, 2df) 73 (14.1)
Other prescription drugs 38 (17.8) 40 (24.8) 30 (21.0) 0.262 (X2 2.89, 2df) 108 (20.9)
Missing data 1 (0.6) 1 (0.6) 1 (0.6) - 3 (0.6)
NSAID: non-steroidal anti-inflammatory drug; df: degrees of freedom.
*Reported codeine/dihydrocodeine use.
doi:10.1371/journal.pone.0111038.t001
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included transverse limb defects and bowel atresias. In the Non-
Vascular Disruption Control Group, cases of exomphalos were the
largest number (30 cases, 21% of Group), and the Genetic Cases
were a variety of single gene disorders and fetuses with multiple
anomalies but with normal karyotype.
Recreational drug use
The presence of drugs was confirmed in the hair of 87 (16.8%)
women. Ten women only had dihydrocodeine or codeine
detectable (five periconceptually, four in the first trimester and
one in the second trimester), of whom all reported this use as over
the counter medication in the questionnaire. We therefore
assumed that these drugs were taken for analgesic use only. After
excluding them from analysis, there were 77 women (14.9%) with
evidence of recreational drugs in their hair sample (Table 3). Ten
women had evidence of poly-recreational drug use. The most
common recreational drug was cannabis, detected in 68 women
(13.2% of the study population). Cocaine was used by 18 women
(3.5%); ten women (1.9%) used cocaine and cannabis together. In
cocaine users, the majority (16, 88?9% of users) had the drug
detectable in the second trimester hair sample, with eight women
(44.4% of users) and five women (27.8% of users) with drug
detectable in the first trimester and the periconceptual hair sample
respectively, suggesting that drug use did not decrease during
pregnancy. A minority of cannabis users (six women, 8.8% of
users) only had the drug detectable in the periconceptual hair
sample. Cannabis was detected in 39 women (55.7% of users) and
in 52 women (76.5% of users) in the first and second trimester hair
samples respectively. Amphetamines were detected in the hair of
one woman, in combination with cocaine and cannabis. Ketamine
was detected in the hair of one woman. No barbiturates or
benzodiazepines were detected in any hair samples. Vasoactive
drug use (cocaine or amphetamine) was detected in 18 women
(22.2% of users).
Recreational drug use and social factors
Women whose hair tested positive for recreational drugs had a
higher median IMD deprivation score (33.34 compared to 22.04
in non-recreational drug users, p = 0?001, Table 4). Women
testing positive for recreational drug use were younger than those
testing negative (median maternal age 25.0 years compared to
29.5 years, p = 0?003). They were more likely to be smokers
(current or within the last 6 months) and unemployed, compared
to women who did not take recreational drugs (Table 4). Ethnicity
and being single (no current partner) were not associated with
recreational drug use. There was no association between use of
alcohol, folic acid, aspirin, paracetamol (acetaminophen), antibi-
otics or other medication with recreational drug use.
Table 2. Number of women recruited per group.
Group Number of women % of total recruited % of group
Vascular Disruption Cases
Gastroschisis 59 11.4 27.7
Facial cleft 44 8.5 20.7
Renal anomaly 41 7.9 19.2
Cardiac defect 39 7.5 18.3
Non NTD Central Nervous System anomaly 20 3.9 9.4
*Other vascular 10 1.9 4.7
Total Vascular Disruption Cases 213 41.2 100
Non-Vascular Disruption Control Group
Exomphalos 30 5.8 21.0
Congenital Diaphragmatic Hernia 29 5.6 20.3
NTD 25 4.8 17.5
Talipes 23 4.4 16.0
**Aneuploidy 21 4.1 14.7
DGenetic 15 2.9 10.5
Total Non Vascular Disruption Controls 143 27.7 100
Normal Controls
Normal structure and karyotype 161 31.1 -
Total Control Group (Non-Vascular Disruption and Normal) 304 58.8 -
Total recruited 517 100 -
NTD: neural tube defect.
* Transverse limb defects (7 cases), bowel atresia (3 cases: duodenal atresia or ileal atresia) .
** Trisomy 21 (10 cases), trisomy 18 (2 cases), 1 case each of trisomy 13, 45 X0, XXX, triploidy, unbalanced translocation, 15q deletion, terminal deletion of chromosome
5.
D Skeletal dysplasia (8 cases), multiple abnormalities (6 cases), autosomal dominant polycystic kidney disease (2 cases).
Cardiac anomalies included large septal defects, hypoplastic left or right heart, Ebstein’s anomaly, tetralogy of Fallot, transposition of the great arteries, left atrial
isomerism, valvular atresias and double outlet right ventricle.
Other CNS anomalies included agenesis of corpus callosum, Dandy Walker spectrum, cerebellar hypoplasia, posterior fossa cyst, porencephalic cyst, severe
ventriculomegaly and holoprosencephaly.
Renal anomaly: multicystic or dysplastic kidneys, lower urinary outflow tract obstruction.
doi:10.1371/journal.pone.0111038.t002
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Recreational drugs and fetal anomaly
To explore the relationship between a specific anomaly and
recreational drug use, women with that abnormality (renal,
cardiac, CNS, etc) were compared with women in the Normal
Control Group. Women with a fetus affected by a gastroschisis
anomaly were significantly more likely to have recreational drugs
detected in their hair when compared with women in the Normal
Control Group (15, 25.4% vs 21, 13%, p= 0.028, Table 5).
However when comparing an age-matched Normal Control group
to women with a fetus affected by gastroschisis, there were no
significant differences in detection of recreational drugs (15, 25.4%
vs 12, 20.3%, p= 0.105).
Women with a fetus affected by a non-NTD CNS anomaly
were significantly more likely to have recreational drugs detected
in their hair when compared with women in the Normal Control
Group (7, 35% vs 21, 13%, p= 0.010, Table 5). There was no
significant difference in maternal age between the groups (mean
29.85, SD 4.44, range 22–39 years vs mean 29.79, SD 5.597,
range 18–42 years, p = 0.155).
Women with a fetus affected by a vascular disruption anomaly
such as bowel atresia or transverse limb defect were more likely to
test positive for recreational drug use, but this difference did not
reach statistical significance. When the recreational drugs that are
considered to be vasoactive (cocaine, MDMA, and amphetamines)
were analysed separately from cannabinoids, the significant
associations were lost, possibly due to the small numbers of
positive cases. THC use alone was not significantly associated with
any fetal anomaly.
There was no significant association between recreational drugs
in the hair and the other anomaly groups: cardiac defect, renal,
facial cleft, exomphalos, NTD, CDH, talipes, aneuploidy, and
genetic (Table 5).
Other factors analysed and fetal anomaly
The deprivation score (IMD) was significantly higher in women
whose fetus was affected by talipes (mean IMD score 34.986
SD16.35) compared to women in the Normal Control Group
(mean IMD score 26.896 SD13.82, p= 0.04), but IMD was not
associated with any other fetal anomalies. Smoking, either current
or past, was significantly more common in women with a fetus
affected by a gastroschisis compared to the Normal Control Group
(25 women, 43.1% vs 36 women, 22.5%, p= 0.04), but was not
associated with any other fetal anomaly. When compared to the
Normal Control Group, women with a fetus affected by a
gastroschisis (19 women, 32.2% vs 26 women, 16.1%, p= 0.014)
or a genetic syndrome (7 women, 46.7% vs 26 women, 16.1%,
p= 0.009) were significantly more likely to be single, but this was
not associated with any other fetal anomaly. There were no
associations between alcohol use, ethnicity, or employment status
with any fetal abnormality.
Compared to women in the Normal Control Group, women
with a fetus affected by gastroschisis were significantly younger
(Normal Control Group mean age 29.796 SD 6, range 18–42 vs
gastroschisis mean age 23.786 SD 4.79, range 18–37 respectively,
p = 0.00001), and those with a fetus affected by an isolated
exomphalos or aneuploidy were significantly older compared to
the Normal Control Group (exomphalos mean age 32.606 SD
7.03, range 18–50 p= 0.046; aneuploidy mean age 34.056 SD
7.40, range 18–45, p = 0.018). There was no association between
maternal age and other fetal anomalies.
Type of fetal anomaly and use of other drugs
Folic acid use was reported by 372 women (72%). There was no
significant difference in the mean maternal age of folic acid users
and non-users (29.6365.82 versus 28.6166.94 years respectively,
Table 3. Presence of recreational drugs according to gestational time period analysed.
Drug type Time period of recreational drug use
Recreational drug use at
anytime
% of recreational drug
users % of total
Periconceptual 1st trimester 2nd trimester
Cannabis 52 39 29 68 88?3 13.2
Cocaine 15 8 5 18 23?4 3.5
Ketamine 1 1 0 1 1?3 0.2
MDMA 1 0 0 1 1?3 0.2
MDMA: methylenedioxymethamphetamine.
doi:10.1371/journal.pone.0111038.t003
Table 4. Social factors associated with recreational drug use.
Social factor Recreational drug use OR 95% CI p value
yes no total
Median IMD deprivation score 33.34 22.04 - — - 0?001*
Median maternal age (years) 25.00 29.50 - - - 0?003*
SmokingD (%) 32 (26.0%) 91 (74.0%) 123 (100%) 2.75 1.65–4.58 0.000217**
Non-smokers (%) 44 (11.3%) 344 (88.7%) 388 (100%)
Unemployed (%) 34 (21.3%) 126 (78.8%) 160 (100%) 1.97 1.20 to 3.23 0.011**
Employed (%) 43 (12.0%) 314 (88.0%) 357 (100%)
Dsmoking currently or in the last 6 months; OR: Odds Ratio; CI: confidence interval; *Mann-Whitney U test; **Chi squared test.
doi:10.1371/journal.pone.0111038.t004
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p= 0.126). Women with a fetus affected by a gastroschisis were
significantly less likely to report taking periconceptual folic acid
(Table 6). There were no associations between folic acid use with
any other fetal abnormality.
Antibiotic prescription medication use was reported by 73
women (14.6%). Antiviral medication use, such as zanamivir or
oseltamivir for treatment or prevention of influenza, was reported
by six women (1.2%). Use of non-steroidal anti-inflammatory
medication was reported by 29 women (5.6%). Prescription
medication use other than antibiotics or antivirals was reported by
108 women (20.9%). There was no significant difference in the
maternal age of prescription medication users and non-users.
Women with a fetus affected by gastroschisis or exomphalos were
less likely to report taking prescription medication (Table 6).
There were no associations between the use of aspirin, paracet-
amol (acetaminophen), codeine, or DHC, and over-the-counter
medication with any fetal abnormality.
Regression analysis
There was more than one significantly associated factor in the
analysis of women whose fetus had a gastroschisis. Binary logistic
regression showed that after including all significantly associated
variables, young maternal age still remained significantly associ-
ated with gastroschisis (Table 7) and no folic acid use nearly
reached significance. Recreational drug use was not significantly
associated with the presence of a gastroschisis.
Table 5. Type of fetal anomaly and recreational drug use.
Fetal anomaly Recreational drug use (% of anomaly category) OR 95%CI p value
yes no Total
vs Normal Control (X2,
df)
Normal Control Group 21 (13%) 140 (87%) 161 - - -
Vascular Disruption Cases 36 (16.9%) 177 (83.1%) 213 - - -
Gastroschisis 15 (25.4%) 44 (74.6%) 59 2.27 1.08–4.78 0.028 (4.84, 1)
Non NTD CNS anomaly 7 (35.0%) 13 (65.0%) 20 3.59 1.29–10.02 0.010 (6.56, 1)
Facial cleft 4 (9.1%) 40 (90.9%) 44 0.67 0.22–2.05 0.48 (0.50, 1)
Renal anomaly 4 (9.8%) 37 (90.2%) 41 0.72 0.23–2.23 0.57 (0.33, 1)
Cardiac defect 3 (7.7%) 36 (92.3%) 39 0.56 0.16–1.97 0.36 (0.85, 1)
Other vascular 3 (30.0%) 7 (70.0%) 10 2.86 0.69–11.92 0.43 (1.70, 1)
Non-Vascular Disruption Control
Group
20 (14%) 123 (86%) 143 - - -
Exomphalos 2 (6.7%) 28 (93.3%) 30 0.48 0.11–2.15 0.32 (0.97, 1)
Aneuploidy 1 (4.8%) 20 (95.2%) 21 0.33 0.04–2.62 0.27 (1.2, 1)
CDH 4 (13.8%) 25 (86.2%) 29 1.07 0.34–3.37 0.91 (0.012, 1)
Talipes 5 (21.7%) 18 (78.3%) 23 1.85 0.62–5.52 0.26 (1.25, 1)
NTD 6 (24.0%) 19 (76.0%) 25 2.12 0.75–5.87 0.15 (2.09, 1)
Genetic 2 (13.3%) 13 (86.7%) 15 1.03 0.22–4.87 0.98 (0.01, 1)
OR: Odds Ratio compared to Normal Control Group; CI: confidence interval; NTD: neural tube defect; df: degrees of freedom.
doi:10.1371/journal.pone.0111038.t005
Table 6. Fetal anomalies and non-recreational drug use.
Fetal anomaly Periconceptual folic acid
yes no total OR 95% CI p value (X2, df)
Normal Control Group 124 (77.5%) 36 (22.5%) 160 0.33 0.18–0.63 0.001 (11.99, 1)
Gastroschisis 31 (53.4%) 27 (46.6%) 58
Prescription medication
Yes no total OR 95% CI p value (X2, df)
Normal Control Group 60 (37.5%) 100 (62.5%) 160 - - -
Gastroschisis 12 (20.7%) 46 (79.3%) 58 0.43 0.21–0.89 0.020 (5.44, 1)
Exomphalos 5 (16.7%) 25 (83.3%) 30 0.33 0.12–0.92 0.035 (4.87, 1)
OR: Odds Ratio.
Missing cases were excluded.
doi:10.1371/journal.pone.0111038.t006
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There was no interaction between recreational drug use and
maternal age in the analysis of women whose fetus had a non-
NTD CNS anomaly. For exomphalos, binary logistic regression
found that older maternal age and not taking prescription
medication still remained significantly associated with exomphalos
(Table 8).
Discussion
The main findings in this study are that using objective
measurement in the hair, recreational drug use was higher in
women whose fetus has a gastroschisis but this association no
longer held when an age-matched control group was used or when
other factors were considered. Only young maternal age remained
significantly associated with fetal gastroschisis. In this cohort, as in
our previous study [8] and many other studies, young women were
significantly more likely to use recreational drugs, and young
maternal age was strongly associated with gastroschisis. This
current larger study has been able to tease out the confounding
factors, the main one being young maternal age and shows that
recreational drug use per se is not associated with gastroschisis.
In addition, we observed that recreational drug use was
significantly higher in women whose fetus had a non-neural tube
defect CNS anomaly. One previous study described ten infants
with developmental delay and congenital cerebral anomalies who
were found to have had in utero exposure to vasoactive drugs such
cocaine and heroin [26], and another case has similarly reported a
possible association of septo-optic dysplasia with multiple maternal
recreational drug use [27]. Our study suggests a significant
association between recreational drug use that includes vasoactive
drugs and the non-vasoactive drug tetrahydrocannabinol, and
CNS defects. Our findings should be validated further in a larger
group of pregnancies where the fetus is affected by a non-neural
tube defect CNS anomaly.
This is an objective study of recreational drug use in a large
group of women with age-matched controls covering a broad
range of fetal abnormalities. Our study shows that nearly 15% of
women recruited had objective evidence of recreational drug use,
mostly of cannabis, during the periconceptual and first trimester
time periods, which reduced as pregnancy progressed. Recrea-
tional drug use was associated with higher deprivation score and
younger maternal age.
A strength of the study is that we used an unbiased assessment of
drug-taking, which did not rely on woman providing subjective
information. The objective method used can assess recreational
drug use over a period of weeks to months [6,7,22,25], and avoids
inaccurate, self, and usually under-reporting. This method allows
for timing of drug exposure to be assessed by analysing hair at
different distances from the hair root, as hair grows continuously at
an average rate of 1 cm per month [8]. This methodology has
been previously validated in forensic situations [8,22]. Cosmetic
treatments are known to alter drug concentration but do not
eliminate drugs from the hair and studies demonstrate that the
stability of drugs long term in the hair is high [7]. Other
techniques, such as analysis of neonatal meconium, do not allow
the timing of drug use to be elucidated. A weakness of the study is
that it was not possible to measure the quantity of recreational
drugs taken, nor the exact time period of the fetal exposure. In
addition we relied on self-reporting of use of other drugs such as
folic acid, NSAIDs, paracetamol (acetaminophen), over-the-
counter and prescribed medication, and all are subject to recall
bias. Finally, only a proportion of the recreational drugs identified
in this study were in the vasoactive group of drugs that are
considered to be associated with fetal defects. It is possible,
therefore, that the inability to demonstrate a relationship between
gastroschisis and recreational drug use in this study is due to the
low numbers of amphetamine and cocaine users that we recruited.
Nevertheless, our findings highlight the strong influence of
maternal age and must call into question the previously held view
that these vasoactive drugs are a cause of gastroschisis and its
increasing prevalence.
Our findings differ to those published in a study by Draper et al
[25] which demonstrated a significantly higher level of any
recreational drugs and vasoconstrictive recreational drugs in
particular, defined as cocaine, amphetamines, and ecstasy, in
women with a fetal gastroschisis. This study differed from ours in a
Table 7. Binary logistic regression.
Variable p value
Maternal age *0.000002
Folic acid use 0.052
Prescription medication 0.090
Recreational drug use 0.398
Smoking currently or in the last 6 months 0.488
Married or living with partner 0.834
Dependent variable is fetus with gastroschisis.
doi:10.1371/journal.pone.0111038.t007
Table 8. Binary logistic regression.
Variable p value
Maternal age *0.023
Prescription medication *0.040
Dependent variable is fetus with exomphalos.
doi:10.1371/journal.pone.0111038.t008
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number of ways. In their group of 144 women with fetal
gastroschisis and 432 matched normal controls, Draper et al
performed hair analysis on only 39.5% of the cases and 26.3% of
controls, and in the majority of women, the authors relied on self-
reported recreational drug use and revised the estimates using data
from hair analysis. When compared with our findings, the
population in the study by Draper et al had a far lower prevalence
of any type of recreational drug use and vasoactive recreational
drug use in controls (5.5%) and cases (16.7%). In our study,
vasoactive drugs were used by 22?2% of recreational drug users,
but only 6.8% women with a fetal gastroschisis had evidence of
this drug type in their hair. The different findings could also be
due to the different populations studied, which in the Draper et al
study were from three UK regional congenital anomaly registers,
and the different methodologies used.
The incidence of recreational drug use in women whose fetus
had anomalies that are considered to be vascular in origin, such as
transverse limb defects and bowel atresias, was higher than in the
rest of the cohort and although it did not reach statistical
significance, this may reflect the small numbers of cases in this
anomaly group. Unlike previous epidemiological studies [28], we
did not find an association between facial clefts and recreational
drug use.
Women whose fetus had a gastroschisis were significantly less
likely to have taken folic acid periconceptually. This association
however just failed to reach significance when other factors such as
maternal age and prescription medication were taken into
consideration. This may be due to the small numbers in our
study. One observational case control study in Western Australia
did not find any evidence of folate being an important factor in the
prevention of birth defects other than neural tube defects [29]. It is
not clear from the data, however, how many cases of gastroschisis
were included in their analysis since the authors grouped ‘‘other’’
fetal abnormalities together for consideration (n= 119, intestinal
atresias, choanal atresia, diaphragmatic hernia, gastroschisis,
exomphalos, tracheo-oesophageal fistula). In another study, a
Canadian birth defect registry, a significant increase in the
prevalence of abdominal wall defects, and most notably gastros-
chisis, was observed after the introduction of folate fortification of
grain products. The authors concluded that this was likely to be
related to pre-existing increasing trends in gastroschisis incidence
documented in several regions around the world rather than the
effect of folic acid supplementation itself [30]. Draper et al [25] did
not report periconceptual folic acid use in their study, but they had
similar findings for maternal age, and smoking. Findings from a
recent case control study supports the association of longer
duration of folic acid use with a reduced risk of gastroschisis [32].
Our study shows that use of over-the-counter and prescription
medication during pregnancy is common. Over 20% of women in
this study reported use of prescription medication in their
pregnancy, and nearly 15% reported antibiotic medication use.
Use of non-steroidal anti-inflammatory medication was reported
by 5.6% of women. The association of a reduced risk of
gastroschisis in women who used prescription medication did
not remain significant after adjusting for other factors such as
maternal age, folic acid use, recreational drug use, smoking or
having a partner. For exomphalos however, the association of a
reduced risk remained after adjusting for maternal age, and the
reason for this is unclear.
Conclusion
In conclusion, this large study, using objective measurement of
recreational drug exposure during the periconceptual period and
the first and second trimesters of pregnancy, shows a high use of
recreational drugs during pregnancy. Our findings strengthen the
previously observed association between certain fetal anomalies,
such as CNS defects and recreational drugs, but do not confirm
the association with gastroschisis.
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